Parkway Life Real Estate Investment Trust

DB:3P51 Stock Report

Market Cap: €1.6b

Parkway Life Real Estate Investment Trust Valuation

Is 3P51 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3P51 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3P51 (€2.56) is trading below our estimate of fair value (€7.05)

Significantly Below Fair Value: 3P51 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3P51?

Key metric: As 3P51 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 3P51. This is calculated by dividing 3P51's market cap by their current earnings.
What is 3P51's PE Ratio?
PE Ratio22.5x
EarningsS$98.54m
Market CapS$2.21b

Price to Earnings Ratio vs Peers

How does 3P51's PE Ratio compare to its peers?

The above table shows the PE ratio for 3P51 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.2x
HABA Hamborner REIT
63x11.0%€515.7m
AGR Assura
19x19.9%UK£1.3b
LTC LTC Properties
17.5x-4.7%US$1.8b
SILA Sila Realty Trust
61.5x8.4%US$1.4b
3P51 Parkway Life Real Estate Investment Trust
22.5x17.4%€2.2b

Price-To-Earnings vs Peers: 3P51 is good value based on its Price-To-Earnings Ratio (22.5x) compared to the peer average (40.2x).


Price to Earnings Ratio vs Industry

How does 3P51's PE Ratio compare vs other companies in the Global Health Care REITs Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
3P51 22.5xIndustry Avg. 26.8xNo. of Companies5PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 3P51 is good value based on its Price-To-Earnings Ratio (22.5x) compared to the Global Health Care REITs industry average (26.8x).


Price to Earnings Ratio vs Fair Ratio

What is 3P51's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3P51 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 3P51's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 3P51 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.56
€3.25
+27.0%
9.2%€3.59€2.80n/a4
Nov ’25€2.56
€3.25
+27.0%
9.2%€3.59€2.80n/a4
Oct ’25€2.84
€3.15
+11.0%
12.5%€3.53€2.51n/a4
Sep ’25€2.52
€2.97
+18.0%
9.8%€3.23€2.48n/a4
Aug ’25€2.48
€2.97
+19.5%
9.8%€3.23€2.48n/a4
Jul ’25€2.36
€3.02
+28.0%
11.8%€3.47€2.47n/a4
Jun ’25€2.41
€3.02
+25.7%
11.8%€3.47€2.47n/a4
May ’25€2.41
€3.02
+25.3%
11.8%€3.47€2.47n/a4
Apr ’25€2.32
€3.07
+32.4%
9.6%€3.47€2.64n/a4
Mar ’25€2.38
€3.09
+29.8%
11.1%€3.50€2.66n/a3
Feb ’25€2.37
€2.98
+26.0%
11.4%€3.32€2.64n/a2
Jan ’25€2.46
€3.01
+22.0%
8.2%€3.33€2.67n/a4
Dec ’24€2.33
€3.01
+29.1%
8.2%€3.33€2.67n/a4
Nov ’24€2.27
€3.01
+32.3%
8.2%€3.33€2.67€2.564
Oct ’24€2.48
€3.05
+23.1%
7.9%€3.32€2.66€2.844
Sep ’24€2.58
€3.04
+17.6%
5.6%€3.26€2.78€2.524
Aug ’24€2.59
€3.05
+17.4%
5.6%€3.27€2.79€2.484
Jul ’24€2.57
€3.05
+18.6%
5.1%€3.26€2.78€2.365
Jun ’24€2.53
€3.06
+21.0%
5.1%€3.27€2.79€2.415
May ’24€2.60
€3.06
+17.7%
5.1%€3.27€2.79€2.415
Apr ’24€2.68
€3.20
+19.3%
5.7%€3.37€2.87€2.325
Mar ’24€2.93
€3.20
+9.1%
5.7%€3.37€2.87€2.385
Feb ’24€3.10
€3.13
+1.0%
5.6%€3.35€2.86€2.374
Jan ’24€2.50
€3.11
+24.5%
8.8%€3.53€2.85€2.464
Dec ’23€2.69
€3.36
+24.7%
8.0%€3.62€2.96€2.334
Nov ’23€2.78
€3.36
+21.1%
8.0%€3.62€2.96€2.274

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies